13 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.
Ono Pharmaceutical Co., Ltd
Substituted (aryloxy)alkanoic acids as antagonists of slow-reacting substance of anaphylaxis.
Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: a novel class of leukotriene antagonists.
Leukotriene receptor antagonists. 2. The [[(tetrazol-5-ylaryl)oxy]methyl]acetophenone derivatives.
Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic
Merck Frosst Centre for Therapeutic Research
A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.
Merck Frosst Center for Therapeutic Research
Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.
Novartis Pharma AG
Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists.
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
Roche Research Center
Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.
ICI Pharmaceuticals Group
The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.
Rorer Central Research